TD Cowen Rates Alkermes (ALKS) buy, $50 Price Target
TD Cowen analyst Joseph Thome reiterates a buy rating on Alkermes plc with a $50 price target as the stock changes hands around $51.06, a 2.09% downside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
TD Cowen rated Alkermes plc ($ALKS) "buy" with a $50 price target on June 22, 2026.
Since the rating, $ALKS is up 14.2% after 1 week, up 14.2% after 1 month and down 10.4% to date (from the $46.02 close on Jun 22, 2026).
ALKS
Alkermes plc
Key Points
- TD Cowen analyst Joseph Thome reiterated a buy rating on Alkermes plc (NasdaqGS: ALKS) with a $50 price target on June 22, 2026.
- TD Cowen's $50 price target implies 2.09% downside from Alkermes plc's ($ALKS) current $51.06 share price.
- The stock trades around $51.06, hovering near its 52-week high of $55.67 and well above its 50-day moving average of $48.94.
- Wall Street coverage shows overall positive sentiment with 17 analyst opinions resulting in a consensus buy recommendation and a mean price target of $56.65.
Get $ALKS trade alerts by text
We text you when insiders, Congress or big funds trade $ALKS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Alkermes plc alert may contain errors. Disclosures
TD Cowen Keeps Buy Rating on Alkermes Stock
TD Cowen has kept its positive stance on Alkermes plc (NasdaqGS: ALKS), with analyst Joseph Thome reiterating a buy rating on the shares alongside a $50 price target on June 22, 2026. This view comes as the biopharmaceutical company sees steady attention from major financial institutions tracking its neurological and specialty drug portfolio.
TD Cowen vs. the S&P 500
Hypothetical returns from TD Cowen's disclosed trades, not real profit or advice. How we model this.
$ALKS price target
Alkermes plc daily closes and this analyst's $50 target. Not advice.
Alkermes Stock Trades Near Recent Highs
Shares of Alkermes changed hands around $51.06, placing the equity near the upper boundary of a 52-week trading range that stretches from a low of $26.99 to a peak of $55.67. The current trading level rests above both the 50-day moving average of $48.94 and the 200-day moving average of $38.54. The company commands a market capitalization of roughly $7.41 billion and carries a trailing P/E ratio of 116.26, while its forward P/E ratio sits at 24.43 based on anticipated earnings.
Wall Street Analyst Views and Price Targets
Other financial firms have adjusted their perspectives on Alkermes in recent months. On September 22, 2026, RBC Capital reiterated an outperform rating with a $56 price target. On the same day, Baird maintained an outperform rating and lifted its target to $61 from $58. Needham followed on September 21, 2026, by reiterating a buy rating with a $62 target. Earlier in the summer, firms like Piper Sandler, Stifel, and JP Morgan also updated their targets.
Across the broader analyst community, the consensus recommendation stands at a buy, drawn from 17 professional opinions. Individual price targets span from a low of $38.00 up to a high of $78.00, yielding a mean price target of $56.65.
Understanding the Business Behind Alkermes
Headquartered in Dublin, Ireland, Alkermes operates as a specialty biopharmaceutical company focused on developing pharmaceutical treatments for complex central nervous system disorders. Its commercial lineup features therapeutic options for schizophrenia, bipolar disorder, and alcohol or opioid dependence, alongside proprietary drug delivery technologies shared with global pharmaceutical partners.
What to Watch Next for Alkermes
Market participants will follow upcoming corporate updates and the company's next financial results scheduled for October 28, 2026. These reports will offer fresh insight into revenue trajectories and product sales across the firm's commercial portfolio.
Related Filing Alerts
Source: TD Cowen's rating change on $ALKS (Jun 22, 2026). Written by software, not financial advice. How we make alerts